Formal Grant of US Patent
Summary by AI BETAClose X
18 March 2026
Futura Medical plc
("Futura", "the Group" or the "Company")
Formal Grant of US Patent
Further to its announcement on 5 February 2026, Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to announce that the US Patent Office has formally granted its US continuation patent No. 12,576,152 which will provide additional protection for Eroxon® (including formulation derivatives such as the Eroxon® Intense formulation) and women's product WSD4000 (currently in development) until 2040 in the US.
Under the terms of its existing licence agreement with Haleon, the granting of this patent is expected to trigger a US patent milestone payment of US$2.5 million.
Contacts:
|
Futura Medical plc
|
Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO
|
investor.relations@futuramedical.com +44 (0)1483 685 670
|
|
Panmure Liberum Nominated Adviser and Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Turner Pope Investments (TPI) Ltd - Broker |
Guy McDougall, Andrew Thacker |
+44 (0)20 3657 0050 |
|
|
|
|
|
Alma Strategic Communications |
Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters |
+44 (0)20 3405 0205 futura@almastrategic.com |
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Sexual health issues are prevalent in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date. Multiple distribution partnerships are in place for Eroxon, across major consumer markets.
The WSD4000 is a prototype product designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund